Connect with us

Hi, what are you looking for?

Jewish Business News


Teva to sue Dr. Reddy’s over generic Copaxone

Teva confirmed that it will continue to vigorously defend its Copaxone intellectual property rights.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

copaxone_03 TEVA

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has confirmed that it has received the first paragraph IV notice for a generic version of its three-times-a-week Copaxone 40 mg/mL treatment. Copaxone 40 mg/mL is protected by two Orange Book patents that expire in 2030.

The notice was from Dr. Reddy’s Laboratories Inc. and Teva said that it will continue to vigorously defend its Copaxone intellectual property rights against infringement wherever they are challenged. Teva said it plans to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the lawsuit will trigger a 30 month stay of US Food and Drug Administration (FDA) approval of Dr. Reddy’s ANDA.




You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.